N-(2-((1-(3,6,9,12-tetraoxapentadec-14-ynyl)-1H-1,2,3-triazol-4-yl)bis(4-methoxyphenyl)methylamino)phenyl)-4-acetamidobenzamide | 1416735-08-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-((1-(3,6,9,12-tetraoxapentadec-14-ynyl)-1H-1,2,3-triazol-4-yl)bis(4-methoxyphenyl)methylamino)phenyl)-4-acetamidobenzamide
• 英文别名: 4-acetamido-N-[2-[[bis(4-methoxyphenyl)-[1-[2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethyl]triazol-4-yl]methyl]amino]phenyl]benzamide
• CAS: 1416735-08-4
• 化学式: C₄₃H₄₈N₆O₈
• 分子量: 776.89
• InChiKey: BTXLACNNDTWZLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.61
• 重原子数：
  57.0
• 可旋转键数：
  23.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  156.32
• 氢给体数：
  3.0
• 氢受体数：
  12.0

反应信息

• 作为产物：
  描述：

  1,1-双(4-甲氧基苯基)-2-丙炔-1-醇 在 potassium hydrogensulfate 、 copper(l) iodide 、 sodium hydride 、 三乙胺 、 乙酰氯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 14.0h， 生成 N-(2-((1-(3,6,9,12-tetraoxapentadec-14-ynyl)-1H-1,2,3-triazol-4-yl)bis(4-methoxyphenyl)methylamino)phenyl)-4-acetamidobenzamide
  参考文献：
  名称：

  Design of pH responsive clickable prodrugs applied to histone deacetylase inhibitors: A new strategy for anticancer therapy

  摘要：

  The aim of this study was to develop clickable prodrugs bearing a tunable pH responsive linker designed for acidic pH-mediated release of histone deacetylase inhibitors. HDACi are an important class of molecules belonging to the epigenetic modulators used for innovative cancer strategies. The behavior of these prodrugs was determined by a bioluminescence resonance energy transfer assay in living tumor cells. This work demonstrated that this innovative type of clickable prodrugs entered cancer cells and showed restored anti proliferative properties attributed to the effective release of the HDAC inhibitors. A correlation between kinetic studies, dose responses, and biological activities was obtained, making such clickable prodrugs good candidates for new strategies in epigenetic-oriented anticancer therapies. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejpb.2013.03.006

文献信息

• POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT
  申请人：Bertrand Philippe

  公开号：US20140219925A1

  公开（公告）日：2014-08-07

  Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents.

  新型聚合物纳米载体或颗粒及其作为药物和/或诊断试剂的用途。
• NANO VECTEURS OU PARTICULES POLYMERES ET LEUR UTILISATION COMME MEDICAMENT ET/OU AGENT DE DIAGNOSTIC
  申请人：Centre National de la Recherche Scientifique

  公开号：EP2726107A1

  公开（公告）日：2014-05-07
• [EN] POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT<br/>[FR] NANO VECTEURS OU PARTICULES POLYMERES ET LEUR UTILISATION COMME MEDICAMENT ET/OU AGENT DE DIAGNOSTIC
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2013001244A1

  公开（公告）日：2013-01-03

  La présente invention concerne des nanovecteurs ou particules polymères et leur utilisation comme médicament et/ou agent de diagnostic.
• Design of pH responsive clickable prodrugs applied to histone deacetylase inhibitors: A new strategy for anticancer therapy
  作者：Régis Delatouche、Iza Denis、Marion Grinda、Fatima El Bahhaj、Estelle Baucher、Floraine Collette、Valérie Héroguez、Marc Grégoire、Christophe Blanquart、Philippe Bertrand

  DOI：10.1016/j.ejpb.2013.03.006

  日期：2013.11

  The aim of this study was to develop clickable prodrugs bearing a tunable pH responsive linker designed for acidic pH-mediated release of histone deacetylase inhibitors. HDACi are an important class of molecules belonging to the epigenetic modulators used for innovative cancer strategies. The behavior of these prodrugs was determined by a bioluminescence resonance energy transfer assay in living tumor cells. This work demonstrated that this innovative type of clickable prodrugs entered cancer cells and showed restored anti proliferative properties attributed to the effective release of the HDAC inhibitors. A correlation between kinetic studies, dose responses, and biological activities was obtained, making such clickable prodrugs good candidates for new strategies in epigenetic-oriented anticancer therapies. (C) 2013 Elsevier B.V. All rights reserved.